June 19, 2006 -- Vytorin from Merck and Schering-Plough outperformed Crestor from AstraZeneca, as Merck’s Zocor is about to lose patent protection; PRA International, a CRO, will pay 85 million Euros to buy another CRO, Pharma Bio-Research; Novartis recalled all Vapor Patch products; ISTA Pharma in-licensed two ophthalmology drug candidates from Senju Pharma; Poniard Pharma rose from the ashes of NeoRx; Medarex received an SPA for ipilimumab against metastatic melanoma; Amgen reported Aranesp helped heart failure patients with anemia; Endo began marketing its Synera pain patch; CV Thera said Ranexa reduced angina frequency as a first-line therapy; Cytogen released positive data from a myeloma trial of Quadramet;and New River presented positive data about its abuse-resistant ADHD drug. The Centient Biotech 200™ fell 56 points to 3571.33, a loss of 1.54%. More details...
